---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-229714"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2026-05-19T12:07:26+00:00"
generated_at: "2026-05-19T12:10:18.157842+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Artiva CFO departs; CEO assumes financial duties; Miralles becomes President

## Summary
- CFO Thad Huston to leave May 22; receives $135k cash severance and 9 months COBRA; search begun.
- CEO Fred Aslan becomes principal financial and accounting officer after stepping down as President.
- Diego Miralles resigns from board, appointed President and Head of R&D; $600k salary, 45% bonus target.
- Miralles awarded inducement equity: 232,500 options and 77,500 RSUs under 2025 Inducement Plan.
- Board size reduced from 8 to 7; Miralles's consulting agreement ended May 17.

## SEC filing metadata
- accession: 0001193125-26-229714
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2026-05-19T12:07:26+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/0001193125-26-229714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/artv-20260518.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-229714
- JSON: https://secwatch.observer/filing/0001193125-26-229714.json
- Plain text: https://secwatch.observer/filing/0001193125-26-229714.txt

## Key facts
- Executive change
  Diego Miralles resigned as Director at Artiva Biotherapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), effective May 18, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/0001193125-26-229714-index.htm
- Executive change
  Fred Aslan was appointed as principal financial officer and principal accounting officer at Artiva Biotherapeutics, Inc..
  - Action: appointed
  - Role: principal financial officer and principal accounting officer
  source text: On May 18, 2026 (the “Effective Date”), Fred Aslan, M.D. resigned as President of the Company in connection with Dr. Miralles’s appointment as President and Head of Research and Development of the Company as described below.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/0001193125-26-229714-index.htm
- Executive change
  Thad Huston departed as Chief Financial Officer at Artiva Biotherapeutics, Inc..
  - Action: separated
  - Role: Chief Financial Officer
  source text: On May 18, 2026, Thad Huston and the Company agreed to Mr. Huston’s separation from his position as Chief Financial Officer and principal financial and accounting officer of the Company, effective May 22, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/0001193125-26-229714-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.